Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treated Subjects With Chronic HBV Infection With Low-level Viremia (LLV)
Conditions
Interventions
TQA3605 tablets plus NAs
TQA3605 Placebo plus NAs
Locations
19
China
Beijing Ditan Hospital Capital Medical University
Beijing, Beijing Municipality, China
Beijing Youan Hospital, Capital Medical Universitybeijing Institute of Hepatology
Beijing, Beijing Municipality, China
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China
Zunyi Medical University Affiliated Hospital
Zunyi, Guizhou, China
Start Date
November 14, 2024
Primary Completion Date
August 25, 2025
Completion Date
December 10, 2025
Last Updated
January 26, 2026
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions